GLP1R and type 2 diabetes mellitus: Indeed, an actuarial analysis based on data from 12 large randomized clinical trials, encompassing over 87 000 patients with T2D and at least moderately increased albuminuria, supports the implementation of a four‐pillared approach (RASis, SGLT2is, a nsMRA and GLP‐1 RAs) in this population; this strategy was associated with a 4.4% absolute risk reduction in major adverse CV events (nonfatal myocardial infarction, nonfatal stroke or CV death) over 3 years.57